MX376350B - Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos. - Google Patents

Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.

Info

Publication number
MX376350B
MX376350B MX2015012855A MX2015012855A MX376350B MX 376350 B MX376350 B MX 376350B MX 2015012855 A MX2015012855 A MX 2015012855A MX 2015012855 A MX2015012855 A MX 2015012855A MX 376350 B MX376350 B MX 376350B
Authority
MX
Mexico
Prior art keywords
polypeptide
immune response
response against
vaccine vectors
against enteric
Prior art date
Application number
MX2015012855A
Other languages
English (en)
Other versions
MX2015012855A (es
Inventor
Billy Hargis
Daad Abi-Ghanem
Lisa Bielke
Luc Berghman
Neil R Pumford
Olivia B Faulkner
Sherryll Layton
Original Assignee
Univ Arkansas
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas, Texas A & M Univ Sys filed Critical Univ Arkansas
Publication of MX2015012855A publication Critical patent/MX2015012855A/es
Publication of MX376350B publication Critical patent/MX376350B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a vectores para vacuna que son capaces de inducir una respuesta inmune contra bacterias entéricas y métodos para usar los mismos. Los vectores para vacuna incluyen un polinucleótido que codifica para un polipéptido PAL. El polipéptido PAL se puede expresar sobre la superficie del vector para vacuna. El vector para vacuna también puede incluir un segundo polipéptido que codifica para un polipéptido inmunoestimul ante tal como un polipéptido CD 154 o un polipéptido HMGBl.
MX2015012855A 2013-03-15 2014-03-14 Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos. MX376350B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790301P 2013-03-15 2013-03-15
PCT/US2014/027416 WO2014152508A1 (en) 2013-03-15 2014-03-14 Compositions and methods of enhancing immune responses to enteric pathogens

Publications (2)

Publication Number Publication Date
MX2015012855A MX2015012855A (es) 2016-07-21
MX376350B true MX376350B (es) 2025-03-07

Family

ID=51581229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012855A MX376350B (es) 2013-03-15 2014-03-14 Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.

Country Status (18)

Country Link
US (3) US10376571B2 (es)
EP (2) EP2968423A4 (es)
JP (1) JP6530742B2 (es)
KR (1) KR102239207B1 (es)
CN (1) CN105142653B (es)
AR (1) AR095313A1 (es)
AU (1) AU2014239557B2 (es)
BR (1) BR112015023024B1 (es)
CA (1) CA2906079C (es)
CL (2) CL2015002741A1 (es)
EA (1) EA033538B1 (es)
HK (1) HK1219045A1 (es)
MX (1) MX376350B (es)
MY (1) MY173901A (es)
PH (1) PH12015502135A1 (es)
SG (1) SG11201507421XA (es)
WO (1) WO2014152508A1 (es)
ZA (1) ZA201506466B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
AU2008318357B2 (en) * 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
MX376350B (es) * 2013-03-15 2025-03-07 Univ Arkansas Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3452069A4 (en) * 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
CN106124772B (zh) * 2016-06-15 2018-05-04 金华职业技术学院 一种基于omp18检测空肠弯曲菌的elisa检测试剂盒及其应用
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112019025792A2 (pt) 2017-06-07 2020-07-07 Spark Therapeutics, Inc. agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
WO2021242798A1 (en) * 2020-05-26 2021-12-02 Synlogic Operating Company, Inc. Surface display of proteins on recombinant bacteria and uses thereof

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2131069T3 (es) 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2312667C (en) 1991-10-25 2002-11-19 Immunex Corporation Novel cytokine
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
CA2143299A1 (en) 1992-09-04 1994-03-17 Brenda J. Allan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
AU1059095A (en) 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
PT812206E (pt) 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
ES2214541T3 (es) 1995-06-07 2004-09-16 Immunex Corporation Muteina de cd40l.
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
WO1999032138A1 (en) 1997-12-19 1999-07-01 Immunex Corporation Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
ATE403728T1 (de) 1998-09-04 2008-08-15 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen- träger
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
WO2000063395A1 (en) 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1210114A4 (en) * 1999-08-20 2004-01-02 Gen Hospital Corp OUTER MEMBRANE PROTEIN A, PEPTIDOGLYCAN ASSOCIATED LIPOPROTEIN AND MUREINLIPOPROTEIN AS THERAPEUTIC OBJECTIVES FOR THE TREATMENT OF SEPSIS
US7118751B1 (en) 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
DE60011560T2 (de) 1999-12-28 2005-08-18 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
WO2001055317A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
PT1267899E (pt) 2000-03-17 2005-11-30 Pharmacia & Upjohn Co Llc Vacinas de salmonella com ssa inactivados
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
WO2002036769A2 (en) 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
PT1407004E (pt) 2001-05-15 2009-08-31 Ortho Mcneil Janssen Pharm Iniciação ex-vivo para produção de linfócitos t citotóxicos específicos de ligando-cd40 para tratar doenças autoimunes e alérgicas
US20030060410A1 (en) 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
AU2002358771B2 (en) 2001-12-19 2009-04-23 Alcedo Biotech Gmbh Use of HMGB proteins and nucleic acids that code therefor
JP4660092B2 (ja) 2001-12-21 2011-03-30 イミユネツクス・コーポレイシヨン 組換えポリペプチド
AU2003215254A1 (en) 2002-02-13 2003-09-04 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
WO2004046338A2 (en) 2002-11-20 2004-06-03 North Shore-Long Island Jewish Research Institute Use of hmgb polypeptides for increasing immune responses
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
EP1569684A4 (en) 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
ATE493431T1 (de) 2003-11-21 2011-01-15 Ace Biosciences As An der oberfläche befindliche campylobacter jejuni-polypeptide
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
JP2008508855A (ja) 2004-04-27 2008-03-27 インターツェル・アクチェンゲゼルシャフト Ｔｄ抗原
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
EP1768698A4 (en) 2004-06-17 2009-01-28 Medimmune Inc IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
EP1814576A2 (en) 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
CA2577125C (en) 2004-10-07 2016-01-12 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
GB0423681D0 (en) 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
EP1909834A2 (en) 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
PT1949913E (pt) 2005-10-07 2010-08-24 Proyecto Biomedicina Cima Sl Associação imunoestimuladora para a profilaxia e o tratamento da hepatite c
EP1951862B1 (en) 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
CN101064542B (zh) 2006-04-30 2010-12-08 中兴通讯股份有限公司 Mimo ofdm系统中发射天线选择与自适应调制方法
AU2007283731B2 (en) * 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
US20100166788A1 (en) * 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
US20100292309A1 (en) 2007-03-08 2010-11-18 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
JP2011502165A (ja) 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
AU2008318357B2 (en) 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
WO2010148541A1 (zh) * 2009-06-26 2010-12-29 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的胜肽的免疫原组成物及使用方法
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
WO2011091255A1 (en) 2010-01-21 2011-07-28 The Board Of Trustees Of The University Of Arkansas Vaccine vectors and methods of enhancing immune responses
MX377650B (es) 2010-06-09 2025-03-11 Univ Arkansas Vacuna y métodos para reducir una infección por campylobacter.
BR112014011443A2 (pt) 2011-11-11 2017-05-02 Nutrition Physiology Company Llc bactérias do ácido láctico e seu uso como suplementos alimentares para aves domésticas
BR112014018732A8 (pt) 2012-02-01 2017-07-11 Univ Arizona Composições imunogênicas contra campylobacter e usos das mesmas
WO2014028776A1 (en) * 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
ES2809220T3 (es) 2012-10-29 2021-03-03 Univ Arkansas Nuevos adyuvantes mucosos y sistemas de administración
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
MX376350B (es) * 2013-03-15 2025-03-07 Univ Arkansas Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.

Also Published As

Publication number Publication date
MX2015012855A (es) 2016-07-21
EP2968423A4 (en) 2016-11-09
KR102239207B1 (ko) 2021-04-09
CL2017002971A1 (es) 2018-03-16
AU2014239557B2 (en) 2019-01-03
AU2014239557A2 (en) 2016-01-14
US10716840B2 (en) 2020-07-21
HK1219045A1 (zh) 2017-03-24
CN105142653A (zh) 2015-12-09
US20190351042A1 (en) 2019-11-21
SG11201507421XA (en) 2015-10-29
EP3578190A1 (en) 2019-12-11
BR112015023024A2 (pt) 2017-11-14
AU2014239557A1 (en) 2015-10-15
EA201591798A1 (ru) 2016-06-30
JP6530742B2 (ja) 2019-06-12
PH12015502135B1 (en) 2016-01-25
WO2014152508A1 (en) 2014-09-25
CN105142653B (zh) 2019-11-15
CA2906079C (en) 2022-08-23
CA2906079A1 (en) 2014-09-25
US20160038581A1 (en) 2016-02-11
KR20150130480A (ko) 2015-11-23
AR095313A1 (es) 2015-10-07
BR112015023024B1 (pt) 2022-04-19
EP2968423A1 (en) 2016-01-20
US11013792B2 (en) 2021-05-25
US10376571B2 (en) 2019-08-13
JP2016515133A (ja) 2016-05-26
EA033538B1 (ru) 2019-10-31
NZ711761A (en) 2021-08-27
CL2015002741A1 (es) 2016-02-12
ZA201506466B (en) 2023-05-31
PH12015502135A1 (en) 2016-01-25
MY173901A (en) 2020-02-26
US20200297832A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX376350B (es) Vectores para vacuna y uso de los mismos para aumentar la respuesta inmune contra patógenos entericos.
EA202091039A1 (ru) Аденовирусные векторы и пути их применения
MX2020004488A (es) Adenovirus y usos de estos.
MX2020004487A (es) Adenovirus y usos de estos.
CR20160145A (es) Proteínas de unión al antígeno gitr
EA201692254A1 (ru) Иммуномодулирующие прогениторные (имп) клетки
MX2015010555A (es) Composiciones y metodos para mejorar las respuestas inmunes ante una infeccion por eimeria o una infeccion limitante por eimeria.
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
MA43124A (fr) Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse
MX350306B (es) Vacuna y metodos para reducir una infeccion por campylobacter.
EA201391183A1 (ru) Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин
MA42845A (fr) Souches vaccinales de listeria de recombinaison et méthodes d'utilisation desdites souches dans l'immunothérapie anticancéreuse
CL2023003217A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
TN2014000518A1 (en) Reassortant btv and ahsv vaccines
MX2020004492A (es) Adenovirus y usos de los mismos.
CL2019000705A1 (es) Nuevos promotores.
IT201600116554A1 (it) Probiotic yeasts as novel vaccination vectors

Legal Events

Date Code Title Description
FG Grant or registration